Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials
Wei Zheng, Xiao-Hong Li, Xiaomin Zhu, et al.
Journal of Affective Disorders (2019) Vol. 250, pp. 123-131
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, et al.
Psychopharmacology (2021) Vol. 239, Iss. 1, pp. 15-33
Closed Access | Times Cited: 112
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
Depression and Anxiety Disorders
Oğuz Karamustafalıoğlu, Hüseyin Yumrukçal
(2025), pp. 335-476
Closed Access | Times Cited: 7
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Jennifer Swainson, Alexander McGirr, Pierre Blier, et al.
The Canadian Journal of Psychiatry (2020) Vol. 66, Iss. 2, pp. 113-125
Open Access | Times Cited: 79
Comparison of cognitive dysfunction between schizophrenia and bipolar disorder patients: A meta-analysis of comparative studies
Wen Li, Fu-Chun Zhou, Ling Zhang, et al.
Journal of Affective Disorders (2020) Vol. 274, pp. 652-661
Closed Access | Times Cited: 77
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 40
Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression
Xingbing Huang, Wei Zheng
ALPHA PSYCHIATRY (2023) Vol. 24, Iss. 6, pp. 244-246
Open Access | Times Cited: 25
Electroconvulsive therapy in treatment resistant depression
Subha Subramanian, Ruthzaine Lopez, Charles F. Zorumski, et al.
Journal of the Neurological Sciences (2021) Vol. 434, pp. 120095-120095
Closed Access | Times Cited: 42
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subha Subramanian, Simon Haroutounian, Ben Julian A. Palanca, et al.
Journal of the Neurological Sciences (2022) Vol. 434, pp. 120152-120152
Closed Access | Times Cited: 34
Clinical efficacy of adjunctive esketamine anesthesia in electroconvulsive therapy for major depressive disorders: A pragmatic, randomized, controlled trial
Li Ren, Qibin Chen, Jin Gao, et al.
Psychiatry Research (2024) Vol. 335, pp. 115843-115843
Closed Access | Times Cited: 6
Efficacy of electroconvulsive therapy as a potential first‑choice treatment in treatment‑resistant depression (Review)
Simona Trifu, Anca Sevcenco, Mónica Stanescu, et al.
Experimental and Therapeutic Medicine (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 35
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Anya Ragnhildstveit, Matthew Slayton, Laura Jackson, et al.
Brain Sciences (2022) Vol. 12, Iss. 3, pp. 382-382
Open Access | Times Cited: 22
Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use
Kazi Hassan, William M. Struthers, Aditya Sankarabhotla, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 16
Adjunctive transcranial alternating current stimulation for patients with major depressive disorder: A systematic review and meta-analysis
Wei Zheng, Dong-Bin Cai, Sha Nie, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 10
Stanford neuromodulation therapy for treatment-resistant depression: a systematic review
Xian-Jun Lan, Dong-Bin Cai, Qi-Man Liu, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 10
Nitrogen‐containing heterocyclic compounds: A ray of hope in depression?
Diksha Choudhary, Bhupinder Kumar, Rajwinder Kaur
Chemical Biology & Drug Design (2024) Vol. 103, Iss. 2
Closed Access | Times Cited: 3
Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial
Qing-Bin Zeng, D. Zou, Xingbing Huang, et al.
Journal of Affective Disorders (2024) Vol. 368, pp. 320-328
Closed Access | Times Cited: 3
Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy
Nicholas J. Ainsworth, Amir A. Sepehry, Fidel Vila-Rodríguez
Journal of Ect (2019) Vol. 36, Iss. 2, pp. 94-105
Closed Access | Times Cited: 24
Recent advances in electroconvulsive therapy in clinical practice and research
Fahad Mukhtar, William T. Regenold, Sarah H. Lisanby
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>
Xingbing Huang, Xiong Huang, Hongbo He, et al.
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 901-908
Open Access | Times Cited: 15
The involvement of GABAergic system in the antidepressant-like effect of agmatine
Vivian B. Neis, Axel Fogaça Rosado, Gislaine Olescowicz, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2020) Vol. 393, Iss. 10, pp. 1931-1939
Closed Access | Times Cited: 12
Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety
Yecun Liu, Jiguo Yang, Yuanxiang Liu
Journal of Psychiatric Research (2024) Vol. 175, pp. 218-226
Closed Access | Times Cited: 1
Comparison of the Efficacy Between Standard Measurement-Base Care (MBC) and Enhanced MBC for Major Depressive Disorder: A Pilot Study
Yuru He, Xing Wang, Zuowei Wang, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 1465-1473
Open Access | Times Cited: 1
Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression
Zhang Jianjing, Hongjun Tian, Jie Li, et al.
Psychiatry Research (2020) Vol. 287, pp. 112907-112907
Open Access | Times Cited: 11
Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials
Xiaomei Li, Zhan-Ming Shi, Peijia Wang, et al.
General Psychiatry (2020) Vol. 33, Iss. 3, pp. e100117-e100117
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top